- Home
- CAC vs OMER Comparison
CAC vs OMER Comparison
Compare CAC & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAC
- OMER
- Stock Information
- Founded
- CAC 1875
- OMER 1994
- Country
- CAC United States
- OMER United States
- Employees
- CAC N/A
- OMER N/A
- Industry
- CAC Major Banks
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- CAC Finance
- OMER Health Care
- Exchange
- CAC Nasdaq
- OMER Nasdaq
- Market Cap
- CAC N/A
- OMER 188.1M
- IPO Year
- CAC 1997
- OMER 2009
- Fundamental
- Price
- CAC $43.10
- OMER $3.65
- Analyst Decision
- CAC Hold
- OMER Strong Buy
- Analyst Count
- CAC 3
- OMER 5
- Target Price
- CAC $47.33
- OMER $18.00
- AVG Volume (30 Days)
- CAC 62.5K
- OMER 928.7K
- Earning Date
- CAC 07-29-2025
- OMER 08-06-2025
- Dividend Yield
- CAC 3.91%
- OMER N/A
- EPS Growth
- CAC 2.54
- OMER N/A
- EPS
- CAC 3.09
- OMER N/A
- Revenue
- CAC $184,324,000.00
- OMER N/A
- Revenue This Year
- CAC $40.83
- OMER N/A
- Revenue Next Year
- CAC $5.29
- OMER $468.75
- P/E Ratio
- CAC $13.92
- OMER N/A
- Revenue Growth
- CAC 13.26
- OMER N/A
- 52 Week Low
- CAC $33.83
- OMER $2.95
- 52 Week High
- CAC $50.07
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- CAC 70.29
- OMER 54.74
- Support Level
- CAC $42.85
- OMER $3.00
- Resistance Level
- CAC $43.78
- OMER $3.25
- Average True Range (ATR)
- CAC 0.98
- OMER 0.24
- MACD
- CAC 0.37
- OMER 0.10
- Stochastic Oscillator
- CAC 95.06
- OMER 83.33
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.